title: Bone marrow stromal cells combined with oxiracetam influences the expression of B-cell lymphoma 2 in rats with ischemic stroke.
abstract: This study aimed to investigate the combination effects of bone marrow stromal cells (BMSCs) and oxiracetam for ischemic stroke. Forty Sprague Dawley female rats (220 ± 20 g) were subjected to a 2-hour ischemic middle cerebral artery occlusion (MCAO)-24 hours reperfusion model. The rats were randomly divided into 4 groups. Rats from BMSCs group, oxiracetam group, and BMSCs + oxiracetam group accepted injection of BMSCs (3 × 10(6) cells), oxiracetam (800 mg/kg), and BMSCs + oxiracetam, respectively. Rats from control group did not receive any interventions after ischemia reperfusion. The neurologic function was examined by modified neurological severity scores (mNSS). B-cell lymphoma 2 (Bcl-2) expression and apoptosis were detected by immunohistochemistry and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining. The mNSS was decreased in all treatment groups and that in BMSCs + oxiracetam group was lower than BMSCs group and oxiracetam group (P < .05). The expression of Bcl-2 was unregulated in all treatment groups (P < .05), and similarly, the expression of Bcl-2 in BMSCs + oxiracetam group was higher than BMSCs group and oxiracetam group (P < .05). Control group displayed more TUNEL-positive cells than the treatment groups, and BMSCs + oxiracetam group displayed less apoptotic cells than BMSCs group or oxiracetam group (P < .05). Transplantation of BMSCs can promote the recovery of neurologic function in MCAO rats, and the effect of BMSCs combined with oxiracetam was better than the either one. Upregulation of Bcl-2 resulting in a decrease of apoptosis may be one of the mechanisms of BMSCs treatment for cerebral ischemic stroke.
authors.affiliation: Department of Neurology, The First Hospital and Clinical College, Harbin Medical University, Harbin, China.
authors.forename: Chunyan
authors.initials: C
authors.lastname: Wang
authors.affiliation: Department of Neurology, The First Hospital and Clinical College, Harbin Medical University, Harbin, China.
authors.forename: Fangqin
authors.initials: F
authors.lastname: Li
authors.affiliation: Department of Neurology, Hangzhou Hospital of Zhejiang CAPF, Hangzhou, China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Guan
authors.affiliation: Department of Neurology, The First Hospital and Clinical College, Harbin Medical University, Harbin, China.
authors.forename: Lei
authors.initials: L
authors.lastname: Zhu
authors.affiliation: Department of Neurology, The First Hospital and Clinical College, Harbin Medical University, Harbin, China.
authors.forename: Yiping
authors.initials: Y
authors.lastname: Fei
authors.affiliation: Department of Neurology, The First Hospital of Harbin, Harbin, China.
authors.forename: Jiadong
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Department of Neurology, The First Hospital and Clinical College, Harbin Medical University, Harbin, China. Electronic address: yujunpan@ems.hrbmu.edu.cn.
authors.forename: Yujun
authors.initials: Y
authors.lastname: Pan
mesh_terms: D000818:Animals; D001854:Bone Marrow Cells / Q000166:cytology* / Q000378:metabolism; D016026:Bone Marrow Transplantation / Q000379:methods*; D002545:Brain Ischemia / Q000378:metabolism / Q000628:therapy*; D003131:Combined Modality Therapy / Q000379:methods; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005260:Female; D059630:Mesenchymal Stem Cells / Q000166:cytology / Q000378:metabolism*; D018697:Nootropic Agents / Q000494:pharmacology; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D011759:Pyrrolidines / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D020521:Stroke / Q000378:metabolism / Q000628:therapy*; D016896:Treatment Outcome; D015854:Up-Regulation / Q000187:drug effects
chemical_list: D018697:Nootropic Agents; D019253:Proto-Oncogene Proteins c-bcl-2; D011759:Pyrrolidines; C040619:oxiracetam
keywords: BMSCs; Bcl-2; Ischemic stroke; oxiracetam